08.12.13
Boulder, Colo.-based Encision Inc., a medical device company that makes surgical technology to prevent stray electrosurgical burns in minimally invasive surgery, has named Patrick Pace, M.D., its non-executive chairman of the board. Pace has been a director of Encision’s board since April 2012 and has served, and will continue to serve, on the nominating committee.
Pace is an Advisor to EDG Partners, a healthcare focused private equity firm. Pace’s background includes over 10 years of financial experience in the healthcare sector. From 2009 to 2011, he was a managing director at Citadel Securities, where he was part of the inaugural team that helped launch the firm’s investment banking and credit sales and trading efforts. In this capacity, he provided credit analysis for the healthcare sector. From 2006 to 2009, he was a vice president at AIG Investments, where he focused on healthcare investments in the high yield bond market. From 2001 to 2006, Pace held various positions at UBS, including serving as senior analyst in equity research covering the medical device sector from 2003 to 2006. Pace also serves as chairman of the board of directors for Nanospectra Biosciences Inc., a privately held medical device company. He earned his medical degree from the University of Texas Medical School, Houston, and a B.A. in psychology from Vanderbilt University.
“Pat’s medical insight, investment community expertise and leadership skills are very valuable to Encision, our shareholders and our employees,” said Fred Perner, Encision’s CEO.
Encision was founded in 1991 to create technology to improve the safety of laparoscopy. Earlier this year, the company released three new products, including an electrode monitoring system designed to control stray monopolar energy caused by insulation failure and capacitive coupling in surgical instruments.
Pace is an Advisor to EDG Partners, a healthcare focused private equity firm. Pace’s background includes over 10 years of financial experience in the healthcare sector. From 2009 to 2011, he was a managing director at Citadel Securities, where he was part of the inaugural team that helped launch the firm’s investment banking and credit sales and trading efforts. In this capacity, he provided credit analysis for the healthcare sector. From 2006 to 2009, he was a vice president at AIG Investments, where he focused on healthcare investments in the high yield bond market. From 2001 to 2006, Pace held various positions at UBS, including serving as senior analyst in equity research covering the medical device sector from 2003 to 2006. Pace also serves as chairman of the board of directors for Nanospectra Biosciences Inc., a privately held medical device company. He earned his medical degree from the University of Texas Medical School, Houston, and a B.A. in psychology from Vanderbilt University.
“Pat’s medical insight, investment community expertise and leadership skills are very valuable to Encision, our shareholders and our employees,” said Fred Perner, Encision’s CEO.
Encision was founded in 1991 to create technology to improve the safety of laparoscopy. Earlier this year, the company released three new products, including an electrode monitoring system designed to control stray monopolar energy caused by insulation failure and capacitive coupling in surgical instruments.